The results of a clinical trial using bone marrow-derived mesenchymal stromal cells (MSCs) to treat late-stage knee osteoarthritis were published recently, and they came back positive. The trial included both phase 1 and 2 and was designed to determine the safety and efficacy of MSC stem cell therapy.
A battery of tests
During the trial, patients were given a single injection of 1, 10, or 50 million MSCs directly into the knee. The trial used a number of tests associated with knee osteoarthritis, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a common set of standardized questionnaires used by healthcare professionals to evaluate the condition of patients with osteoarthritis of the knee. The WOMAC includes questions relating to pain, stiffness, and the physical functioning of the joints.
Comments are closed.